SEARCH

SEARCH BY CITATION

References

  • 1
    Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122:889.
  • 2
    Wright TL, Donegan E, Hsu H, et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology 1992; 103:317.
  • 3
    Gane EJ, Portmann BC, Naoumov NV, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334:815.
  • 4
    Feray C, Gigou M, Samuel D, et al. The course of hepatitis C infection after liver transplantation. Hepatology 1994; 20:1137.
  • 5
    Feray C, Caccamo L, Alexander GJM, et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. Gastroenterology 1999; 117:619.
  • 6
    Prieto M, Berenguer M, Rayon JM, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology 1999; 29:250.
  • 7
    Berenguer M, Prieto M, Rayon JM, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000; 32:852.
  • 8
    Charlton M, Seaberg E, Wiesner R, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998; 28:823.
  • 9
    Sreekumar R, Gonzalez-Koch A, Maor-Kendler Y, et al. Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation. Hepatology 2000; 32:1125.
  • 10
    Berenguer M, Ferrell L, Watson J, et al. HCV-related fibrosis progression following liver transplantation increase in recent years. J Hepatol 2000; 32:673.
  • 11
    Rosen HR, Shackleton CR, Higa L, et al. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Am J Gastroenterol 1997; 92:14453.
  • 12
    Sheiner PA, Schwartz ME, Mor E, et al. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995; 21:30.
  • 13
    Berenguer M, Prieto M, Cordoba J, et al. Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: association with treatment of rejection. J Hepatol 1998; 28:756.
  • 14
    Berenguer M, Prieto M, San Juan F, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002; 36:202.
  • 15
    Wali M, Harrison RF, Gow PJ, Mutimer D. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut 2002; 51:248.
  • 16
    Gane E, Naoumov N, Qian K, et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996; 110:167.
  • 17
    Papatheodoridis G, Davies S, Dhillon A, et al. The role of different immunosuppression in the long-term histological outcome of HCV reinfection after liver transplantation for HCV cirrhosis. Transplantation 2001; 72:412.
  • 18
    Everson T. Impact of immunosuppressive therapy on recurrence of hepatitis C. Liver Transpl 2002; 8; [Suppl]19.
  • 19
    Crippin JS, McCashland T, Terrault N, Sheiner P, Charlton MR. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002; 8:350.
  • 20
    Forns X, Garcia-Retortillo M, Serrano T, et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003; 39:389.
  • 21
    Everson G, Trotter J, Kugelmas M, et al. Long-term outcome of patients with chronic hepatitis C and decompensated liver disease treated with the LADR protocol (low accelerating-dose regimen). Hepatology 2002; 36:297A.
  • 22
    Garcia-Retortillo M, Forns X, Feliu A, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002; 35:680.
  • 23
    Samuel D, Feray C. Recurrence of hepatitis C virus after liver transplantation. J Hepatol 1999; 31 [Suppl 1]:217.
  • 24
    Sheiner PA, Boros P, Klion FM, et al. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation. Hepatology 1998; 28:831.
  • 25
    Singh N, Gayowski T, Wannstedt CF, et al. Interferon alfa for prophylaxis of recurrent viral hepatitis C in liver transplant recipients: a prospective, randomised, controlled trial. Transplantation 1998; 65:82.
  • 26
    Mazzaferro V, Tagger A, Schiavo M, et al. Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment. Transplant Proc 2001; 33:1355.
  • 27
    Reddy R, Fried M, Dickson R, et al. Interferon α-2b and ribavirin vs placebo as early treatment in patients transplanted for hepatitis C end-stage liver disease: results of a multicenter randomised trial (abstract). Gastroenterology 2002; 122:199A.
  • 28
    Feray C, Samuel D, Gigou M, et al. An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: antiviral effects and risk of rejection. Hepatology 1995; 22:1084.
  • 29
    Dousset B, Conti F, Houssin D, Calmus Y. Acute vanishing bile duct syndrome after interferon therapy for recurrent HCV infection in liver-transplant recipients. N Engl J Med 1994; 330:1160.
  • 30
    Gaidano AC, Mosnier JF, Durand F, et al. Alpha-interferon-induced rejection of a hepatitis C virus-infected liver allograft tolerated with a low dosage immunosuppressive regimen. Transplantation 1995; 59:1627.
  • 31
    Wright TL, Combs C, Kim M, et al. Interferon-alpha therapy for hepatitis C virus infection after liver transplantation. Hepatology 1994; 20:773.
  • 32
    Gane EJ, Lo SK, Riordan SM, et al. A randomised study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation. Hepatology 1998; 27:1403.
  • 33
    Cotler SJ, Ganger D, Kaur S, et al. Daily interferon therapy for hepatitis C virus infection in liver transplant recipients. Transplantation 2001; 71:261.
  • 34
    Gane EJ, Tibbs CJ, Ramage JK, Portmann BC, Williams R. Ribavirin therapy for hepatitis C infection following liver transplantation. Transpl Int 1995; 8:61.
  • 35
    Cattral MS, Krajden M, Wanless IR, et al. A pilot study of ribavirin therapy for recurrent hepatitis C virus infection after liver transplantation. Transplantation 1996; 61:1483.
  • 36
    Jain A, Eghtesad B, Venkataramanan R, et al. Ribavirin dose modification based on renal function is necessary to reduce haemolysis in liver transplant patients with hepatitis C virus infection. Liver Transpl 2002; 8:1007.
  • 37
    Bizollon T, Palazzo U, Ducerf C, et al. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology 1997; 26:500.
  • 38
    Samuel D, Bizollon T, Feray C, et al. Interferon-alfa 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomised study. Gastroenterology 2003; 124:642.
  • 39
    Lavezzo B, Franchello A, Smedile A, et al. Treatment of recurrent hepatitis C in liver transplants: efficacy of a six versus a twelve month course of interferon alpha 2b with ribavirin. J Hepatol 2002; 37:247.
  • 40
    Fischer L, Sterneck M, Valentin-Gamazo C, Feucht HH, Malago M, Broelsch CE. Treatment of severe recurrent hepatitis C after liver transplantation with ribavirin plus interferon alpha. Transplant Proc 1999; 31:494.
  • 41
    Gopal DV, Rabkin JM, Berk BS, et al. Treatment of progressive hepatitis C recurrence after liver transplantation with combination interferon plus ribavirin. Liver Transpl 2001; 7:181.
  • 42
    Ahmad J, Dodson SF, Demetris AJ, Fung JJ, Shakil A. Recurrent hepatitis C after liver transplantation: a non randomised trial of interferon alpha alone versus interferon alpha and ribavirin. Liver Transpl 2001; 10:863.
  • 43
    Alberti A, Belli L, Airoldi A, et al. Combined therapy with interferon and low-dose ribavirin in posttransplantation recurrent hepatitis C: a pragmatic study. Liver Transpl 2001; 10:870.
  • 44
    de Vera M, Smallwood G, Rosado K, et al. Interferon alpha and ribavirin for the treatment of recurrent hepatitis C after liver transplantation. Transplantation 2001; 71:678.
  • 45
    Menon K, Poterucha J, El-Amin O, et al. Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy. Liver Transpl 2002; 8:623.
  • 46
    Shakil A, McGuire B, Crippin J, et al. A pilot study of interferon alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis C. Hepatology 2002; 36:1253.
  • 47
    Firpi R, Abdelmalek M, Soldevila-Pico C, et al. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. Liver Transpl 2002; 8:1000.
  • 48
    Bizollon T, Ahmed SNS, Radenne S, et al. Long-term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence. Gut 2003; 52:283.
  • 49
    Bizollon T, Trepo C. Ribavirin and interferon combination for recurrent post-transplant hepatitis C: which benefit beyond 6 months J Hepatol 2002; 37:274.
  • 50
    Vogel W, Ferenci P, Fontana R, et al. Peginterferon alfa-2a (pegasys) in liver transplant recipients with established recurrent hepatitis C: interim results of an ongoing randomised multicenter trial (abstract). Hepatology 2002; 36:312 A.
  • 51
    Neff G, Montalbano M, Lee Y, et al. Naive treatment results in liver transplant recipients with hepatitis C virus recurrence using pegylated interferon alpha-2b combined with ribavirin. Preliminary results. Hepatology 2002; 36:183 A.
  • 52
    Neff G, Montalbano M, Lee Y, et al. Preliminary treatment results of liver transplant recipients with recurrent hepatitis C virus nonresponsive to interferon alpha-2b and ribavirin using combination pegylated interferon al-pha-2b with ribavirin. Hepatology 2002; 36:183A.
  • 53
    Samuel, Roche B, Roque AM, et al. Treatment of patients with recurrent hepatitis C after liver transplantation with pegylated interferon and ribavirin. Hepatology 2003; 34:531A.
  • 54
    Sheiner PA, Schluger LK, Emre S, et al. Retransplantation for recurrent hepatitis C. Liver Transpl Surg 1997; 3:130.
  • 55
    Rosen HR, Martin P. Hepatitis C infection in patients undergoing liver retransplantation. Transplantation 1998; 66:1612.
  • 56
    Rosen HR, Madden JP, Martin P. A model to predict survival following liver retransplantation. Hepatology 1999; 29:365.
  • 57
    Bouscarat F, Samuel D, Simon F, Debat P, Bismuth H, Saimot A. An observational study (1985–1993) of 11 HIV-1 infected liver transplant recipients. Clin Infect Dis 1994; 19:854.
  • 58
    Samuel D, Duclos Vallee JC, Teicher E, Vittecoq D. Liver transplantation in patients with HIV infection. J Hepatol 2003; 39:3.
  • 59
    Prachalias A, Pozniak A, Taylor C, et al. Liver transplantation in adults co-infected with HIV. Transplantation 2001; 72:1684.
  • 60
    Neff GW, Bonham A, Tsakis A, et al. Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease. Liver Transpl 2003; 9:239.